The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children between two ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

This is not the case with the vaccine devised to combat smallpox or variola virus. The smallpox vaccine is not a form of variola virus, but a preparation of vaccinia (a form of cowpox) virus.

To safeguard against additional cases, either at home or while deployed, the Defense Health Agency and the services have made ...

Clearly, we still have a much longer way to go toward disease elimination. We are by no means "done" vaccinating adolescents ...

An update from Tonix Pharma ( (TNXP) ) is now available. Tonix Pharmaceuticals has partnered with the Kenya Medical Research ...

WHO’S SHOWING UP EARLY? Trump had better hope that his—ah— unorthodox appeal to female voters is paying off. Politico reports ...

Emergent BioSolutions says its smallpox treatment to be evaluated in mpox trial in Africa. On Thursday, Emergent BioSolutions Inc. EBS stock is trading higher on mixed third-quarter earnings and a new ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...